Biomarker Testing in RCC: Current Approaches

Video

David Aggen, MD, PhD reviews how he currently approaches biomarker testing in patients with RCC.

Recent Videos
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.
Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.
Related Content
Managing AEs with Gemcitabine Intravesical System in NMIBC

Managing AEs with Gemcitabine Intravesical System in NMIBC

Gary Steinberg, MD
September 20th 2025
Article

Gary Steinberg, MD, compared the AE profile of the gemcitabine intravesical system for BCG-unresponsive NMIBC with other intravesical therapies.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

A manageable safety profile was observed across 2 expansion doses of the combination in urothelial cancer, consistent with known adverse effects of both drugs.

IDE397 Combo Displays Promising Activity in MTAP-Deletion Urothelial Cancer

Roman Fabbricatore
September 9th 2025
Article

A manageable safety profile was observed across 2 expansion doses of the combination in urothelial cancer, consistent with known adverse effects of both drugs.

Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.

Episode 14: Multidisciplinary Care Insights Across World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mehmet Asim Bilen, MD;Sid Sadler;Kerry R. Schaffer, MD;Mark T. Fleming, MD;Jeff Yorio, MD;Mike Lattanzi, MD;Elizabeth Kessler, MD;Benjamin L. Maughan, MD, PharmD;Alan Tan, MD
September 18th 2025
Podcast

Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.

External validation will be assessed in cohort 2 of the AURORAX-0087A trial to improve recurrence detection for clear cell renal cell carcinoma.

Urine Glycosaminoglycan Scores Show High Sensitivity to Detect ccRCC

Roman Fabbricatore
September 3rd 2025
Article

External validation will be assessed in cohort 2 of the AURORAX-0087A trial to improve recurrence detection for clear cell renal cell carcinoma.

Additional correlative data and further prospective clinical investigations are needed to inform biomarker-directed advanced RCC treatment.

Pembrolizumab Combo Exhibits Sustained Clinical Benefit in Advanced RCC

Roman Fabbricatore
August 22nd 2025
Article

Additional correlative data and further prospective clinical investigations are needed to inform biomarker-directed advanced RCC treatment.